文献速递呼吸衰竭与机械通气消化、代谢与肾脏急症

尼达尼布在进展性纤维化间质性肺疾病患者中的疗效:INBUILD 试验按间质性肺疾病诊断进行的亚组分析——一项随机、双盲、安慰剂对照、平行组试验

Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
PubMed 文献 · Lancet Respir Med · 2020-03-05
一句话结论在进展性纤维化间质性肺疾病(非IPF)患者中,尼达尼布150 mg每日两次可减少FVC下降速率,效应在各诊断亚组间一致。

INBUILD 试验是在15个国家153个中心开展的随机、双盲、安慰剂对照、平行组试验,纳入非IPF的纤维化间质性肺疾病且符合进展标准、FVC≥45%预计值、DLco≥30%且<80%预计值的患者663例。患者按1:1随机接受尼达尼布150 mg每日两次或安慰剂至少52周。按间质性肺疾病诊断分5个预设亚组分析52周FVC下降速率(mL/年),尼达尼布减少FVC下降的效应在各亚组间一致(治疗×亚组×时间交互p=0.41),亚组不良事件与总体人群一致。作者认为,结果提示尼达尼布可减少慢性纤维化间质性肺疾病进展表型患者的FVC下降,与基础诊断无关。

要点

  • 纳入非IPF的纤维化间质性肺疾病、HRCT纤维化范围>10%、FVC≥45%预计值、DLco≥30%且<80%预计值,且筛选前24个月内符合方案定义的进展标准。
  • 663例中慢性过敏性肺炎173例(26%)、自身免疫性间质性肺疾病170例(26%)、特发性非特异性间质性肺炎125例(19%)、无法分类的特发性间质性肺炎114例(17%)、其他间质性肺疾病81例(12%)。
  • 尼达尼布150 mg每日两次减少52周FVC下降速率(mL/年)的效应在各诊断亚组一致:过敏性肺炎73.1(95%CI -8.6至154.8)、自身免疫性间质性肺疾病104.0(21.1至186.9)、特发性非特异性间质性肺炎141.6(46.0至237.2)、无法分类的特发性间质性肺炎68.3(-31.4至168.1)、其他间质性肺疾病197.1(77.6至316.7),治疗×亚组×时间交互p=
  • 亚组中报告的不良事件与总体人群一致。
  • 该试验未按特定诊断亚组设计或把握度来提供尼达尼布获益证据,作者认为结果提示尼达尼布可减少慢性纤维化间质性肺疾病进展表型患者的FVC下降,与基础诊断无关。

适用人群与场景

  • 研究者诊断的非IPF纤维化间质性肺疾病患者,HRCT显示纤维化范围>10%,FVC≥45%预计值,DLco≥30%且<80%预计值。
  • 筛选前24个月内符合方案定义的间质性肺疾病进展标准,尽管已接受临床实践中认为适合该间质性肺疾病的治疗。
  • 本亚组分析纳入至少接受一剂尼达尼布或安慰剂的663例患者,按研究者记录的间质性肺疾病诊断分为5个预设亚组。

诊断标准与关键阈值

  • 方案定义的间质性肺疾病进展标准:筛选前24个月内符合。
  • HRCT纤维化范围>10%;FVC≥45%预计值;DLco≥30%且<80%预计值。

处置流程与药物剂量

  • 尼达尼布150 mg每日两次口服,或安慰剂,至少52周。

研究设计与关键结果

  • INBUILD为随机、双盲、安慰剂对照、平行组试验,在15个国家153个中心开展,2017年2月23日至2018年4月27日招募。
  • 663例至少接受一剂尼达尼布或安慰剂:慢性过敏性肺炎173例(26%)、自身免疫性间质性肺疾病170例(26%)、特发性非特异性间质性肺炎125例(19%)、无法分类的特发性间质性肺炎114例(17%)、其他间质性肺疾病81例(12%)。
  • 尼达尼布 vs 安慰剂减少52周FVC下降速率(mL/年)的效应在各诊断亚组一致:过敏性肺炎73.1(95%CI -8.6至154.8);自身免疫性间质性肺疾病104.0(21.1至186.9);特发性非特异性间质性肺炎141.6(46.0至237.2);无法分类的特发性间质性肺炎68.3(-31.4至168.1);其他间质性肺疾病197.1(77.6至316.7);治疗×亚组×时间交互p=0.41。
  • 亚组中报告的不良事件与总体人群一致。

证据类型、等级与局限

  • 证据类型:随机、双盲、安慰剂对照、平行组试验的预设亚组分析。
  • 试验未按特定诊断亚组设计或把握度来提供尼达尼布获益证据。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,结果提示尼达尼布可减少慢性纤维化间质性肺疾病进展表型患者的间质性肺疾病进展(以FVC下降衡量),与基础间质性肺疾病诊断无关。
  • 该试验未按特定诊断亚组设计或把握度来提供尼达尼布获益证据,亚组结果不能作为特定诊断亚组的获益证据。

指南或共识出处

  • INBUILD 试验(ClinicalTrials.gov,NCT02999178),由勃林格殷格翰资助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The INBUILD trial investigated the efficacy and safety of nintedanib versus placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). We aimed to establish the effects of nintedanib in subgroups based on ILD diagnosis.

METHODS: The INBUILD trial was a randomised, double-blind, placebo-controlled, parallel group trial done at 153 sites in 15 countries. Participants had an investigator-diagnosed fibrosing ILD other than IPF, with chest imaging features of fibrosis of more than 10% extent on high resolution CT (HRCT), forced vital capacity (FVC) of 45% or more predicted, and diffusing capacity of the lung for carbon monoxide (DLco) of at least 30% and less than 80% predicted. Participants fulfilled protocol-defined criteria for ILD progression in the 24 months before screening, despite management considered appropriate in clinical practice for the individual ILD. Participants were randomly assigned 1:1 by means of a pseudo-random number generator to receive nintedanib 150 mg twice daily or placebo for at least 52 weeks. Participants, investigators, and other personnel involved in the trial and analysis were masked to treatment assignment until after database lock. In this subgroup analysis, we assessed the rate of decline in FVC (mL/year) over 52 weeks in patients who received at least one dose of nintedanib or placebo in five prespecified subgroups based on the ILD diagnoses documented by the investigators: hypersensitivity pneumonitis, autoimmune ILDs, idiopathic non-specific interstitial pneumonia, unclassifiable idiopathic interstitial pneumonia, and other ILDs. The trial has been completed and is registered with ClinicalTrials.gov, number NCT02999178.

FINDINGS: Participants were recruited between Feb 23, 2017, and April 27, 2018. Of 663 participants who received at least one dose of nintedanib or placebo, 173 (26%) had chronic hypersensitivity pneumonitis, 170 (26%) an autoimmune ILD, 125 (19%) idiopathic non-specific interstitial pneumonia, 114 (17%) unclassifiable idiopathic interstitial pneumonia, and 81 (12%) other ILDs. The effect of nintedanib versus placebo on reducing the rate of FVC decline (mL/year) was consistent across the five subgroups by ILD diagnosis in the overall population (hypersensitivity pneumonitis 73·1 [95% CI -8·6 to 154·8]; autoimmune ILDs 104·0 [21·1 to 186·9]; idiopathic non-specific interstitial pneumonia 141·6 [46·0 to 237·2]; unclassifiable idiopathic interstitial pneumonia 68·3 [-31·4 to 168·1]; and other ILDs 197·1 [77·6 to 316·7]; p=0·41 for treatment by subgroup by time interaction). Adverse events reported in the subgroups were consistent with those reported in the overall population.

INTERPRETATION: The INBUILD trial was not designed or powered to provide evidence for a benefit of nintedanib in specific diagnostic subgroups. However, its results suggest that nintedanib reduces the rate of ILD progression, as measured by FVC decline, in patients who have a chronic fibrosing ILD and progressive phenotype, irrespective of the underlying ILD diagnosis.

FUNDING: Boehringer Ingelheim.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Wells AU, Flaherty KR, Brown KK, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020. PMID: 32145830. doi:10.1016/S2213-2600(20)30036-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。